RU2005136370A - Трициклические индоловые производные и их применение в лечении болезни альцгеймера - Google Patents
Трициклические индоловые производные и их применение в лечении болезни альцгеймера Download PDFInfo
- Publication number
- RU2005136370A RU2005136370A RU2005136370/04A RU2005136370A RU2005136370A RU 2005136370 A RU2005136370 A RU 2005136370A RU 2005136370/04 A RU2005136370/04 A RU 2005136370/04A RU 2005136370 A RU2005136370 A RU 2005136370A RU 2005136370 A RU2005136370 A RU 2005136370A
- Authority
- RU
- Russia
- Prior art keywords
- methyl
- propyl
- ethyl
- indole
- hydroxy
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 41
- -1 cyano, hydroxy, carboxy Chemical group 0.000 claims 33
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 33
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 31
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 12
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 12
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 208000037259 Amyloid Plaque Diseases 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000005213 alkyl heteroaryl group Chemical group 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000004367 cycloalkylaryl group Chemical group 0.000 claims 2
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000006655 (C3-C8) heteroaryl group Chemical group 0.000 claims 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000006311 cyclobutyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 239000010802 sludge Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/06—Peri-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0309221.0 | 2003-04-23 | ||
| GBGB0309221.0A GB0309221D0 (en) | 2003-04-23 | 2003-04-23 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005136370A true RU2005136370A (ru) | 2006-05-27 |
Family
ID=9957152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005136370/04A RU2005136370A (ru) | 2003-04-23 | 2004-04-21 | Трициклические индоловые производные и их применение в лечении болезни альцгеймера |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20060229302A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1620438A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006524206A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20050111797A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1809573A (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0409622A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2523291A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO5700829A2 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0309221D0 (cg-RX-API-DMAC7.html) |
| IS (1) | IS8135A (cg-RX-API-DMAC7.html) |
| MA (1) | MA27674A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA05011365A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20055442L (cg-RX-API-DMAC7.html) |
| RU (1) | RU2005136370A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004094430A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200508041B (cg-RX-API-DMAC7.html) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1565428A1 (en) * | 2002-11-27 | 2005-08-24 | Elan Pharmaceuticals, Inc. | Substituted ureas and carbamates |
| GB0328900D0 (en) * | 2003-12-12 | 2004-01-14 | Glaxo Group Ltd | Novel compounds |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| GB0411404D0 (en) * | 2004-05-21 | 2004-06-23 | Glaxo Group Ltd | Novel compounds |
| BRPI0515383A (pt) * | 2004-09-21 | 2008-07-22 | Pfizer Prod Inc | n-etil hidroxietilamina útil no tratamento de condições do snc |
| GB0422766D0 (en) * | 2004-10-13 | 2004-11-17 | Glaxo Group Ltd | Novel compounds |
| GB0422765D0 (en) * | 2004-10-13 | 2004-11-17 | Glaxo Group Ltd | Novel compounds |
| GB0422755D0 (en) * | 2004-10-13 | 2004-11-17 | Glaxo Group Ltd | Novel compounds |
| WO2006088705A1 (en) * | 2005-02-14 | 2006-08-24 | Wyeth | Terphenyl guanidines as [beta symbol] -secretase inhibitors |
| GB0506562D0 (en) * | 2005-03-31 | 2005-05-04 | Glaxo Group Ltd | Novel compounds |
| KR20080015079A (ko) | 2005-04-08 | 2008-02-18 | 코멘티스, 인코포레이티드 | 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법 |
| WO2007019078A2 (en) * | 2005-08-03 | 2007-02-15 | Merck & Co., Inc. | Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease |
| WO2007061670A1 (en) * | 2005-11-21 | 2007-05-31 | Amgen Inc. | Beta-secretase modulators and methods of use |
| US7872009B2 (en) | 2005-11-21 | 2011-01-18 | Amgen Inc. | Beta-Secretase modulators and methods of use |
| US7745484B2 (en) | 2005-11-21 | 2010-06-29 | Amgen Inc. | Beta-secretase modulators and methods of use |
| US7838676B2 (en) * | 2005-11-21 | 2010-11-23 | Amgen Inc. | Beta-secretase modulators and methods of use |
| TW200901991A (en) | 2007-05-25 | 2009-01-16 | Amgen Inc | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
| MX2009012608A (es) | 2007-05-25 | 2009-12-07 | Amgen Inc | Compuestos de hidroxietil amina substituidos como moduladores de beta-secretasa y metodos de uso. |
| FR2919288B1 (fr) * | 2007-07-27 | 2009-09-04 | Sanofi Aventis Sa | Derives de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6- carboxamides, leur preparation et leur application en therapeutique. |
| FR2919285B1 (fr) | 2007-07-27 | 2012-08-31 | Sanofi Aventis | Derives de 1-oxo-isoindoline-4-carboxamides et de 1-oxo- 1,2,3,4-tetrahydroisoquinoleine-5-carboxamides, leur preparation et leur application en therapeutique. |
| ATE512968T1 (de) * | 2007-07-27 | 2011-07-15 | Sanofi Aventis | 1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazin-6- carboxamid und 2,3,4,5-tetrahydropyrrolo(1,2-a)- diazepin-7-carboxamid- derivate, ihre herstellung und therapeutische verwendung |
| FR2919286A1 (fr) | 2007-07-27 | 2009-01-30 | Sanofi Aventis Sa | Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique. |
| FR2919289B1 (fr) * | 2007-07-27 | 2009-09-04 | Sanofi Aventis Sa | Derives de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]- diazepine-7-carboxamides, leur preparation et leur application en therapeutique. |
| US9096541B2 (en) | 2012-03-29 | 2015-08-04 | Oklahoma Medical Research Foundation | Inhibition of memapsin 1 cleavage in the treatment of diabetes |
| EP3684767B1 (en) * | 2017-09-22 | 2024-04-24 | Jubilant Epipad LLC | Heterocyclic compounds as pad inhibitors |
| US12043631B2 (en) | 2017-10-13 | 2024-07-23 | Purdue Research Foundation | BACE1 inhibitors for the treatment of Alzheimer's disease |
| US11214579B2 (en) | 2017-10-13 | 2022-01-04 | Purdue Research Foundation | BACE1 inhibitors for the treatment of Alzheimer's disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998033795A1 (en) * | 1997-02-04 | 1998-08-06 | The Regents Of The University Of California | Nanomolar, non-peptide inhibitors of cathepsin d |
| US6207664B1 (en) * | 1998-11-25 | 2001-03-27 | Pfizer Inc. | Squalene synthetase inhibitor agents |
| CA2410680A1 (en) * | 2000-06-30 | 2002-01-10 | Elan Pharmaceuticals, Inc. | Compounds to treat alzheimer's disease |
-
2003
- 2003-04-23 GB GBGB0309221.0A patent/GB0309221D0/en not_active Ceased
-
2004
- 2004-04-21 CN CNA2004800175617A patent/CN1809573A/zh active Pending
- 2004-04-21 EP EP04728567A patent/EP1620438A1/en not_active Withdrawn
- 2004-04-21 CA CA002523291A patent/CA2523291A1/en not_active Abandoned
- 2004-04-21 US US10/553,878 patent/US20060229302A1/en not_active Abandoned
- 2004-04-21 BR BRPI0409622-3A patent/BRPI0409622A/pt not_active IP Right Cessation
- 2004-04-21 WO PCT/EP2004/004244 patent/WO2004094430A1/en not_active Ceased
- 2004-04-21 JP JP2006505223A patent/JP2006524206A/ja not_active Withdrawn
- 2004-04-21 KR KR1020057019979A patent/KR20050111797A/ko not_active Withdrawn
- 2004-04-21 RU RU2005136370/04A patent/RU2005136370A/ru not_active Application Discontinuation
- 2004-04-21 MX MXPA05011365A patent/MXPA05011365A/es not_active Application Discontinuation
-
2005
- 2005-10-05 ZA ZA200508041A patent/ZA200508041B/en unknown
- 2005-10-19 MA MA28563A patent/MA27674A1/fr unknown
- 2005-10-21 CO CO05107375A patent/CO5700829A2/es not_active Application Discontinuation
- 2005-11-17 NO NO20055442A patent/NO20055442L/no not_active Application Discontinuation
- 2005-11-21 IS IS8135A patent/IS8135A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004094430A1 (en) | 2004-11-04 |
| GB0309221D0 (en) | 2003-06-04 |
| CA2523291A1 (en) | 2004-11-04 |
| BRPI0409622A (pt) | 2006-04-18 |
| MA27674A1 (fr) | 2005-12-01 |
| EP1620438A1 (en) | 2006-02-01 |
| JP2006524206A (ja) | 2006-10-26 |
| US20060229302A1 (en) | 2006-10-12 |
| ZA200508041B (en) | 2007-02-28 |
| NO20055442L (no) | 2005-11-17 |
| AU2004232475A1 (en) | 2004-11-04 |
| MXPA05011365A (es) | 2005-11-28 |
| IS8135A (is) | 2005-11-21 |
| CO5700829A2 (es) | 2006-11-30 |
| KR20050111797A (ko) | 2005-11-28 |
| CN1809573A (zh) | 2006-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005136370A (ru) | Трициклические индоловые производные и их применение в лечении болезни альцгеймера | |
| JP7278359B2 (ja) | Ｓｈｐ２の活性を阻害するための化合物および組成物 | |
| JP2006524206A5 (cg-RX-API-DMAC7.html) | ||
| JP7514534B2 (ja) | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 | |
| WO2018195450A1 (en) | Combination therapies with ehmt2 inhibitors | |
| JP2016500119A (ja) | ブルトン型チロシンキナーゼ阻害剤 | |
| JP6696904B2 (ja) | 製剤および医薬組成物 | |
| RU2011116227A (ru) | Пиразолопиридиновые производные как ингибиторы надфн-оксидазы | |
| JP2012512165A (ja) | 四環系ピラジノインドールを用いた多発性硬化症の治療方法 | |
| CA2891122A1 (en) | Methods and compositions for treating schizophrenia | |
| AU2016202670A1 (en) | Methods and Compositions for Improving Cognitive Function | |
| RU2006124863A (ru) | Трициклические производные индолгидроксиэтиламина и их применение при лечении болезни альцгеймера | |
| JP2017525721A (ja) | 認知欠損または認知障害に伴って進行する神経障害のおよび神経変性疾患の処置および予防のための製品 | |
| JP2015519368A5 (cg-RX-API-DMAC7.html) | ||
| BR112014020212B1 (pt) | Aminopirazina, formulação farmacêutica, método para prevenir ou tratar malária em um paciente, processo para a preparação de um derivado de aminopirazina, e, intermediário | |
| RU2008125040A (ru) | ПРОИЗВОДНЫЕ АРИЛ-ИЗОКСАЗОЛ-4-ИЛ-ИМИДАЗО[1.5-a]ПИРИДИНА | |
| KR20250133677A (ko) | 치환된 디하이드로피롤로[3,4-d]피리미딘 화합물 및 의학적 병태 치료에서의 이의 용도 | |
| CN101778634A (zh) | 作为抗淀粉样蛋白的物质的哌仑西平和其衍生物 | |
| JP5690594B2 (ja) | ３−（スルホニル）ピラゾロ［１，５−ａ］ピリミジン−セロトニン５−ＨＴ６受容体のアンタゴニスト、その調製の方法及び使用 | |
| JP2005507411A (ja) | 下肢静止不能症候群の治療における、ニコチン性アセチルコリン受容体アゴニスト。 | |
| CN117979999A (zh) | 使用btk抑制剂和pi3激酶抑制剂的组合治疗癌症的方法 | |
| EP4077329A1 (en) | 1h-pyrazolo[3,4-d]pyrimidine compounds useful for the treatment of platinum-resistant cancer | |
| CN121265611A (zh) | Prc2抑制剂的新用途 | |
| WO2025094035A1 (en) | Toll-like receptor agonists and conjugates thereof | |
| BR112018075663B1 (pt) | Compostos para inibição da atividade de shp2, seu uso, e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20080709 |